We are committed to finding a cure for WM.
BGB-3111: Small Molecule BTK Inhibitor to Treat B-Cell Malignancies
BGB-3111 is a potent and highly selective small molecule BTK inhibitor (Bruton’s Tyrosine Kinase), which we are developing as a monotherapy and in combination with other therapies for the treatment of a variety of lymphomas—the most common form of blood cancer. BGB-3111 blocks the signaling that leads to growth inhibition and cell death in malignant B-cells. We believe, based on our preclinical and clinical data, that BGB-3111 has the potential to be differentiated from ibrutinib in the following aspects:
DOWNLOAD FULL ARTICLE HERE BeiGene | BGB-3111 – BeiGene
Source: http://www.beigene.com/pipeline/clinical-candidates/bgb-3111/
